• The Indian pharmaceutical industry is monitoring potential U.S. tariffs, which could impact exports but may not weaken its global competitiveness.
  • Industry leaders argue that shifting manufacturing to the U.S. is impractical due to capacity constraints and higher costs, potentially raising consumer prices.

The Indian pharmaceutical sector is bracing for potential challenges as U.S. President Donald Trump considers imposing significant tariffs on pharmaceutical imports. Despite the looming changes, industry leaders believe Indian drugmakers will maintain their strong presence in the generics market.

Trump has signaled his intent to introduce tariffs of at least 25% on pharmaceutical imports, with an official decision expected soon. The U.S. remains a crucial market for Indian pharmaceutical exports, accounting for nearly a third of total shipments. In fiscal 2024, India’s pharmaceutical exports to the U.S. were valued at approximately $8.7 billion.

At the BioAsia conference in Telangana, Dr. Reddy’s Laboratories Managing Director GV Prasad emphasized that the industry is awaiting more details before making strategic decisions. He pointed out that moving pharmaceutical manufacturing entirely to the U.S. would be impractical due to limited capacity and increased production costs.

"In reality, to shift all these products from worldwide into the United States is not practical. They don’t have that much capacity, and their costs will rise. Even with tariffs, I think Indian and Chinese companies would be competitive," said Prasad.

Industry analysts warn that the proposed tariffs could lead to higher costs for American consumers and distributors. Nandini Piramal, chairperson of Piramal Pharma, highlighted the company’s adaptability to shifting trade policies, stating that they are prepared to adjust as needed.

India’s pharmaceutical industry plays a key role in lowering healthcare costs in the U.S., supplying nearly half of all generic prescriptions. According to research firm IQVIA, generic drugs generated $408 billion in savings for the U.S. healthcare system in 2022.

Leading pharmaceutical companies such as Sun Pharma, Cipla, Biocon, Lupin, Glenmark Pharma, and Zydus depend heavily on the U.S. market. Despite tariff uncertainties, Indian pharmaceutical firms continue to demonstrate resilience. Dr. Reddy’s Laboratories, for instance, posted a 2% increase in consolidated net profit to Rs 1,413 crore in the quarter ending December 31, 2024, driven by strong global performance.

Edited by Harshajit Sarmah